

Datasheet for 600-401-379-RTU**Ready-To-Use RFP Antibody Pre-adsorbed****Overview**

Description:	Ready-To-Use Anti-RFP (RABBIT) Antibody (Min X Hu Ms & Rt Serum Proteins) - 600-401-379-RTU
Item No.:	600-401-379-RTU
Size:	100 µL
Applications:	ELISA, WB, IF, IHC
Reactivity:	RFP, rRFP
Host Species:	Rabbit

Product Details

Background:	Fluorescent proteins like green fluorescent protein (GFP) and Discosoma Red Fluorescent Protein (DsRFP) are widely used in research. DsRFP is derived from the mushroom anemone <i>Discosoma</i> sp. Despite sharing only 19% similarity, anti-GFP antibodies typically don't recognize DsRFP and vice versa. Structurally, DsRFP is akin to GFP in its overall β -can fold and chromophore-formation chemistry. However, GFP undergoes an extra step in chromophore maturation and maintains a tetrameric structure. By using site-directed mutagenesis, various DsRFP variants have been engineered, enabling the red fluorescent protein to mature as a monomer. These monomeric DsRFP variants—mRFP1, mBanana, mCherry, mHoneydew, mPlum, mOrange, mStrawberry, and mTangerine—provide a diverse range of fluorescent colors. Rockland's RFP polyclonal antibodies, raised against the entire wild-type RFP protein, are expected to recognize all these variant forms. These antibodies have been pre-absorbed to prevent potential cross-reactivity with human, mouse, and rat serum proteins, and have also been confirmed to not react with GFP protein. All Rockland Immunochemical's RFP antibodies undergo stringent affinity purification to ensure high specificity and affinity. Thorough quality control tests guarantee that the final product meets or exceeds the highest standards, ensuring optimal performance in your assays.
Synonyms:	DsRed protein, rDsRed, <i>Discosoma</i> sp. Red Fluorescent Protein, Red fluorescent protein drFP583, sea anemone <i>Discosoma</i> sp. Mushroom, RFP antibody, RFP-RTU, Ready To Use Antibody, RTU Antibody
Host Species:	Rabbit
Clonality:	Polyclonal
Format:	IgG

Target Details

Gene Name:	DsRed
Reactivity:	RFP, rRFP
Immunogen Type:	Recombinant Protein
Immunogen:	The immunogen is a Red Fluorescent Protein (RFP) fusion protein corresponding to the full-length amino acid sequence (234aa) derived from the mushroom anemone Discosoma.
Purity/Specificity:	RTU Anti-RFP was prepared from monospecific antiserum by immunoaffinity chromatography using Red Fluorescent Protein (Discosoma) coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Expect reactivity against RFP and its variants: mCherry, tdTomato, mBanana, mOrange, mPlum, mOrange and mStrawberry. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Rabbit Serum and purified and partially purified Red Fluorescent Protein (Discosoma). No reaction was observed against Human, Mouse or Rat serum proteins.
Relevant Links:	UniProtKB - Q9U6Y8

Application Details

Tested Applications:	ELISA, WB
Suggested Applications:	IF, IHC (Based on references)
Application Note:	Ready-To-Use Anti-RFP is designed to detect RFP and its variants. Ready-To-Use Anti-RFP Rabbit Polyclonal Antibody has been optimized and tested in ELISA and in Western blot at a 1:1000 dilution. This Anti-RFP (RTU) Antibody is sufficient for 10 Western blots. Although not tested, there's a high likelihood that this antibody is functional in immunohistochemistry, immunofluorescence, and immunoprecipitation. Researchers can determine the best concentrations for these applications based on their specific experiments.
Assay Dilutions:	All assays should be optimized by the user. Recommended dilutions (if any) may be listed below.
ELISA:	User Optimized
IF:	User Optimized
IHC:	User Optimized
IP:	User Optimized
WB:	1:1,000


Formulation

Physical State:	Liquid (sterile filtered)
Concentration:	0.005mg/mL by UV absorbance at 280 nm
Buffer:	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Preservative:	0.01% (w/v) Sodium Azide
Stabilizer:	0.01% Bovine Serum Albumin (BSA), 25% (v/v) Glycerol

Shipping & Handling

Shipping Condition:	Wet Ice
Storage Condition:	Store vial at 2-8° C prior to opening. May aliquot contents and freeze at -20° C or below for extended storage. Avoid cycles of freezing and thawing. Centrifuge product if not completely clear after standing at room temperature. Dilute only prior to use.
Expiration:	Expiration date is one (1) year from date of receipt.


Images



Immunofluorescence Microscopy

dYPEL3 frameshift mutations reduce the synaptic contact between nociceptors and Basin-4 neurons. (A) The syb-GRASP technique was used to report the synaptic contact between nociceptors and Basin-4. The spGFP1-10 (red cylinders) and spGFP11 (blue sectors) were expressed in nociceptors and Basin-4, respectively (left). The resulting GRASP signal was visualized by anti-GRASP antibody (green), and the spGFP1-10 that is expressed in nociceptor axon terminals was used as a normalization control (magenta) (right). Scale bar: 10 μ m. (B) The GRASP intensity from each neuropil was normalized by spGFP1-10 intensity and presented as mean $\pm$ s.e.m. (left), as well as in a violin plot to show distribution (right) (n=36 for wt, n=34 for dYPEL3T1-8). Mann-Whitney test. All statistical analysis was two-tailed. **P<0.01. Figure provided by CiteAb. Source: Dis Model Mech, PMID: 32461240.


A



Immunofluorescence Microscopy


dYPEL3 frameshift mutations reduce nociceptive behavior. (A) Nociceptive/class IV da neurons are positive for dYPEL3. A nuclear GFP (GFP-nls, green) was expressed under dYPEL3-GAL4 following immunostaining with anti-Knot antibody (blue). Anti-HRP antibody was used to label all PNS neurons (magenta). Scale bar: 10 μ m. (B) The AITC-induced nociceptive behavior was measured in a wild-type control (wt) and dYPEL3 frameshift mutants (dYPEL3T1-8 and dYPEL3T1-6). The number of larvae that exhibited complete rolling behavior was scored and expressed as a percentage (n=252 for each genotype). The Chi-squared test was performed between the groups. NS, non-significant; ****p<0.0001. Figure provided by CiteAb. Source: Dis Model Mech, PMID: 32461240.

A






Immunofluorescence Microscopy

dYPEL3 is a neuronal gene. (A) The expression pattern of dYPEL3 in the CNS. The InSITE gene trap line for dYPEL3 was used (CG15309-GAL4/dYPEL3-GAL4). GAL4 transcription factor is inserted in the first intron. The introduction of UAS-mCD8::GFP demonstrates the endogenous expression pattern of dYPEL3. Note that the CG15309-GAL4-positive cells elaborate fine processes throughout the CNS. Scale bar: 50 μ m. (B) mCD8::GFP (magenta) was expressed under dYPEL3-GAL4 following immunostaining with anti-Elav (neuronal, green) and anti-Repo (glial, blue) antibodies. (i) The CNS. Cell bodies in 1 and 2 are shown magnified on the top right. (ii,iii) Chordotonal neurons (ii, arrows) and a class III da neuron (iii) in the PNS. iii also shows a class IV da neuron (nociceptor) that is positive for dYPEL3 (arrow). Scale bar: 10 μ m. (C) Quantitation of the Elav-positive and Repo-positive cells that are labeled with CG15309-GAL4. The majority of dYPEL3-positive cells were Elav positive, but none were positive for Repo. Figure provided by CiteAb. Source: Dis Model Mech, PMID: 32461240.



Immunofluorescence Microscopy

dYPEL3 knockout mutants recapitulate the phenotypes in the *dYPEL3* frameshift mutants. (A) The generation of *dYPEL3* knockout (*dYPEL3KO*) flies. Top: the entire *dYPEL3* ORF was deleted using CRISPR/Cas9-mediated homology-directed recombination. Bottom: agarose gel image of PCR-based genotyping. Note that *dYPEL3KO* showed the PCR amplifications specific for DsRed-cassette, but not the ones from wild type. (B) *dYPEL3* knockout reduces AITC-induced behavioral responses. AITC-induced nociceptive behavior was measured in a wild-type control (*wt*) and *dYPEL3* knockout mutants (*dYPEL3KO*). The number of larvae that exhibited complete rolling behavior was scored and expressed as a percentage ($n=252$ for *wt*, $n=203$ for *dYPEL3KO*). The Chi-squared test was performed between the groups. (C) *dYPEL3* knockout caused a reduction in Basin-4 activation upon AITC. GCaMP6f was expressed in Basin-4 neurons. Nociceptors were activated with 10 mM AITC. Ca^{2+} increase in Basin-4 was measured by GCaMP fluorescence and the GCaMP trace over time is shown ($n=47$ for *wt*, $n=46$ for *dYPEL3KO*) (left). The cumulative GCaMP activation from single Basin-4 neurons was measured and presented as $mean \pm s.e.m.$ (middle), as well as in a violin plot to show distribution (right). Mann–Whitney test. (D) *dYPEL3* knockout causes a reduction in syb-GRASP signals between nociceptors and Basin-4. Synaptobrevin-spGFP1-10 and spGFP11 were expressed in nociceptors and Basin-4, respectively. The resulting GRASP signal was visualized by anti-GFP antibody that only recognizes the reconstituted GFP (anti-GRASP) (green), and the spGFP1-10 expressed in nociceptor axon terminals was used as a normalization control (magenta) (left). Scale bar: 10 μm . The GRASP intensity from each neuropil was normalized by spGFP1-10 intensity and presented as $mean \pm s.e.m.$ (middle), as well as in a violin plot to show distribution (right) ($n=32$ for *wt*, $n=80$ for *dYPEL3T1-8*). Mann–Whitney test. *** $P<0.001$ and **** $P<0.0001$. Figure provided by CiteAb. Source: Dis Model Mech, PMID: 32461240.



ELISA


ELISA results of purified Ready-To-Use Rabbit Anti-RFP Antibody Min X Hu Ms and Rt Serum Proteins tested against RFP (Red), Mouse IgG (Blue), Human IgG (Green), and Rat IgG (Purple). Each well was coated in 1.0 µg of antigen. The starting dilution of antibody was 5 µg/mL and the X-axis represents the Log10 of a 3-fold dilution. This titration is a 4-parametre curve fit where the IC50 is defined as the titer of the antibody. The curve representing the RFP as the antigen is shown in red while Mouse IgG, Human IgG, and Rat IgG antigens are shown in blue, green, and purple. Assay performed using Buffer (p/n MB-060-1000), Substrate (p/n TMB-8000), and Conjugate (Goat Anti-Rabbit IgG Antibody HRP at 1:8,500).

Western Blot

Western Blot Results of Ready to Use Rabbit Anti-RFP Antibody. Lane 1: recombinant RFP. Load: 0.05µg. Primary Antibody: Ready to Use Rabbit Anti-RFP Antibody 1:1000 overnight at 4°C. Secondary Antibody: Donkey Anti-Goat HRP (p/n 605-703-125) at 1:40,000 for 30 min RT. Block: BlockOut Buffer (p/n MB-073).

Western Blot

Western Blot of Ready-to-Use Rabbit Anti-RFP Antibody. Lane 1: Opal Prestain Molecular Weight (p/n MB-210-0500). Lane 2: HeLa (p/n W09-000-364). Lane 3: HEK293 (p/n W09-000-365). Lane 4: Cho/K1 (p/n W07-000-359). Lane 5: MDA-MB-231 (p/n W09-001-GK6). Lane 6: A431 (p/n W09-000-361). Lane 7: Jurkat (p/n W09-001-370). Lane 8: NIH/3T3 (p/n W10-000-358). Lane 9: E. coli HCP (p/n 000-001-J08). Lane 10: FLAG (p/n W00-001-383). Lane 11: RFP (p/n 000-001-379). Lane 12: GFP (p/n 000-001-215). Lane 13: GST (p/n 000-001-200). Lane 14: MBP (p/n 000-001-385). Lane 15: Opal Prestain. Primary Antibody: RTU-RFP at 1 µL/mL overnight at 4°C. Secondary Antibody: Goat anti-Rabbit HRP (p/n 611-103-122) at 1:70,000 for 30min at RT. Expect 27kDa seen in lane 11. Unspecific band in lane 3 caused by cross reactivity with secondary antibody.



Western Blot

Western Blot of Ready-to-Use Rabbit Anti-RFP Antibody.

Lane 1: Opal Prestain Molecular Weight (p/n MB-210-0500).

Lane 2: RFP (p/n 000-001-379). Lane 3: Human IgG (p/n 009

-0102). Lane 4: Goat IgG (p/n 005-0102). Lane 5: Mouse IgG

(p/n 010-0102). Primary Antibody: RTU-RFP at 1 μ L/mL

overnight at 4°C. Secondary Antibody: Goat anti-Rabbit HRP

(p/n 611-103-122) at 1:70,000 for 30min at RT. Expect

27kDa seen in lane 2.

References

- Naert T et al. Precise, predictable genome integrations by deep-learning-assisted design of microhomology-based templates. *Nat Biotechnol.* (2026)
- Wang Y et al. Bi-directional communication between intrinsic enteric neurons and ILC2s inhibits host defense against helminth infection. *Immunity.* (2025)
- Khan EU et al. Spinal dI3 neurons are involved in sustained motor adaptation elicited by low-threshold cutaneous afferents. *bioRxiv [Preprint].* (2025)
- Scholz-Carlson E et al. Synaptic targets of circadian clock neurons influence core clock parameters. *Sci Adv.* (2025)
- Drexler R et al. Serotonergic neuron-glioma interactions drive high-grade glioma pathophysiology. *bioRxiv [Preprint].* (2025)
- Iyer AR et al. Circadian rhythms are more resilient to pacemaker neuron disruption in female *Drosophila*. *PLoS Biol.* (2025)
- Leung HH et al. *Drosophila* tweety facilitates autophagy to regulate mitochondrial homeostasis and bioenergetics in Glia. *Glia.* (2024)
- Suthard RL et al. Chronic Gq activation of ventral hippocampal neurons and astrocytes differentially affects memory and behavior. *Neurobiol Aging.* (2023)
- Lowenstein ED et al. Prox2 and Runx3 vagal sensory neurons regulate esophageal motility. *Neuron.* (2023)
- Thankachan, S et al. Low frequency visual stimulation enhances slow wave activity without disrupting the sleep pattern in mice. *Scientific Reports* (2022)
- Lancaster CE et al. Phagosome resolution regenerates lysosomes and maintains the degradative capacity in phagocytes. *J Cell Biol.* (2021)
- Kim JH. et al. Frameshift mutations of YPEL3 alter the sensory circuit function in *Drosophila*. *Dis Model Mech.* (2020)

Disclaimer

This product is for research use only and is not intended for therapeutic or diagnostic applications. Please contact a technical service representative for more information. All products of animal origin manufactured by Rockland Immunochemicals are derived from starting materials of North American origin. Collection was performed in United States Department of Agriculture (USDA) inspected facilities and all materials have been inspected and certified to be free of disease and suitable for exportation. All properties listed are typical characteristics and are not specifications. All suggestions and data are offered in good faith but without guarantee as conditions and methods of use of our products are beyond our control. All claims must be made within 30 days following the date of delivery. The prospective user must determine the suitability of our materials before adopting them on a commercial scale. Suggested uses of our products are not recommendations to use our products in violation of any patent or as a license under any patent of Rockland Immunochemicals, Inc. If you require a commercial license to use this material and do not have one, then return this material, unopened to: Rockland Inc., P.O. BOX 5199, Limerick, Pennsylvania, USA.